Please Wait.....
Report
North America Cancer Photodynamic Therapy Market
Market Report I 2025-10-01 I 350 Pages I Data Bridge Market Research
North America Cancer Photodynamic Therapy market is expected to reach USD 2.46 billion by 2032 from USD 1.53 billion in 2024, growing at a substantial CAGR of 6.2% in the forecast period of 2025 to 2032.
Market Segmentation:
North America Cancer Photodynamic Therapy Market, By Product Type (Photosensitizer Drugs, Photodynamic Therapy Devices, Accessories & Consumables), By Cancer Indication (Skin & Cutaneous Oncology, Head & Neck, Esophageal, Lung, Bladder, Cervical, Prostate, Gastrointestinal, Brain, Others), By Therapy Modality (Standalone Therapy, Adjunctive Therapy, Palliative Therapy, Combination Therapy, Others), By Procedure Technique (External Beam, Interstitial Delivery, Intracavitary Delivery, Intraoperative Delivery, Others), By Disease Stage (Early-Stage Cancer, Locally Advanced, Late-Stage/Metastatic, Recurrent), By Patient Demographics (Pediatric, Adults, Geriatric), By End User (Hospitals, Dermatology & Skin-Cancer Clinics, Oncology Centers, Ambulatory Surgical Centers, Academic & Research Institutes, Others), By Distribution Channel (Direct Tenders, Third-Party Distributors, Online, Others), By Countries (U.S., Canada, Mexico)- Industry Trends and Forecast to 2032.
Overview of the North America Cancer Photodynamic Therapy Market are:
Driver
- Increasing prevalence of cancer
Restrain
- Limited depth of light penetration
Opportunity
- Integration with other cancer therapies
Market Players:
The key market players for North America Cancer Photodynamic Therapy Market are listed below:
- Novartis Pharma AG (Switzerland)
- Galderma SA (Switzerland)
- Bausch Health Companies Inc. (Canada)
- Photocure ASA (Norway)
- ADVANZ PHARMA Corp. (U.K.)
- Sun Pharma Industries Ltd. (India)
- Biofrontera AG (Germany)
- LUMIBIRD SA (France)
- LUZITIN S.A. (Portugal)
- Lumeda Inc. (U.S.)
- ImPact Biotech (U.S.)
- biolitec Holding GmbH & Co KG (Germany)
- Modulight Corporation (Finland)
- Theralase Technologies Inc. (Canada)
TABLE OF CONTENTS
1 INTRODUCTION 94
1.1 OBJECTIVES OF THE STUDY 94
1.2 MARKET DEFINITION 94
1.3 OVERVIEW OF NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET 94
1.4 LIMITATIONS 97
1.5 MARKETS COVERED 97
2 MARKET SEGMENTATION 102
2.1 MARKETS COVERED 102
2.2 GEOGRAPHICAL SCOPE 103
2.3 YEARS CONSIDERED FOR THE STUDY 104
2.4 CURRENCY AND PRICING 104
2.5 DBMR TRIPOD DATA VALIDATION MODEL 105
2.6 MULTIVARIATE MODELLING 108
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 109
2.8 DBMR MARKET POSITION GRID 111
2.9 MARKET END USER COVERAGE GRID 112
2.10 SECONDARY SOURCES 113
2.11 ASSUMPTIONS 114
3 EXECUTIVE SUMMARY 115
4 PREMIUM INSIGHTS 121
4.1 PORTER'S FIVE FORCES 122
4.2 PESTEL ANALYSIS 123
4.3 PRODUCTION CONSUMPTION ANALYSIS 124
4.3.1 INTRODUCTION 124
4.3.2 PRODUCTION SIDE ANALYSIS 124
4.3.2.1 PHOTOSENSITIZER MANUFACTURING 124
4.3.2.2 DEVICE MANUFACTURING 124
4.3.2.3 RESEARCH AND INNOVATION 124
4.3.3 CONSUMPTION SIDE ANALYSIS 124
4.3.3.1 CLINICAL APPLICATION 124
4.3.3.2 TREATMENT VOLUMES AND TRENDS 124
4.3.3.3 DOSAGE AND PROTOCOLS 124
4.3.4 PRODUCTION-CONSUMPTION DYNAMICS 125
4.3.4.1 SUPPLY CONSTRAINTS 125
4.3.4.2 REGIONAL OVERVIEW 125
4.3.4.3 FUTURE OUTLOOK 125
4.3.5 CONCLUSION 125
4.4 COST ANALYSIS BREAKDOWN 126
4.4.1 INTRODUCTION 126
4.4.2 DIRECT MEDICAL COSTS 126
4.4.2.1 COST OF PHOTOSENSITIZERS 126
4.4.2.2 LIGHT DELIVERY SYSTEMS 126
4.4.2.3 HEALTHCARE FACILITY CHARGES 126
4.4.3 INDIRECT COSTS 126
4.4.3.1 PATIENT-RELATED EXPENSES 126
4.4.3.2 POST-TREATMENT MONITORING 126
4.4.4 COMPARATIVE COST-EFFECTIVENESS 126
4.4.5 REIMBURSEMENT AND INSURANCE IMPACT 126
4.4.6 REGIONAL COST VARIATIONS 127
4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES 127
4.4.7.1 TECHNOLOGICAL ADVANCEMENTS 127
4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES 127
4.4.8 CONCLUSION 127
4.5 TECHNOLOGICAL ADVANCEMENTS 128
4.5.1 INTRODUCTION 128
4.5.2 NEXT-GENERATION PHOTOSENSITIZERS 128
4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS 128
4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY 128
4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION 128
4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING 129
4.5.7 RECENT TRENDS AND OUTLOOK 129
4.5.8 CONCLUSION 129
4.6 VALUE CHAIN ANALYSIS 130
4.6.1 INTRODUCTION 130
4.6.2 RESEARCH & DEVELOPMENT 130
4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS 130
4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS 130
4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS 130
4.6.3 MANUFACTURING 130
4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS 130
4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES 130
4.6.4 DISTRIBUTION & LOGISTICS 131
4.6.4.1 SUPPLY CHAIN MANAGEMENT 131
4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS 131
4.6.5 CLINICAL APPLICATION 131
4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS 131
4.6.5.2 TRAINING AND EDUCATION 131
4.6.6 POST-TREATMENT MONITORING & SUPPORT 131
4.6.6.1 FOLLOW-UP CARE 131
4.6.6.2 PATIENT SUPPORT SERVICES 131
4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN 131
4.6.7.1 NANOTECHNOLOGY IN PDT 131
4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING 131
4.6.7.3 PERSONALIZED MEDICINE 132
4.6.8 CONCLUSION 132
4.7 VENDOR SELECTION CRITERIA 133
4.7.1 INTRODUCTION 133
4.7.2 CORE SELECTION CRITERIA 133
4.7.2.1 REGULATORY COMPLIANCE 133
4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT 133
4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY 133
4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS 133
4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT 133
4.7.2.6 SUPPLY CHAIN RELIABILITY 133
4.7.3 RECENT TRENDS IN VENDOR SELECTION 134
4.7.4 RISK FACTORS AND VULNERABILITIES 134
4.7.5 KEY PERFORMANCE INDICATORS 134
4.7.6 STRATEGIC RECOMMENDATIONS 134
4.7.7 CONCLUSION 134
4.8 PATENT ANALYSIS 135
4.8.1 PATENT QUALITY AND STRENGTH 135
4.8.2 PATENT FAMILIES 136
4.8.3 LICENSING AND COLLABORATIONS 136
4.8.4 REGIONAL PATENT LANDSCAPE 137
4.8.5 IP STRATEGY AND MANAGEMENT 139
4.9 SUPPLY CHAIN ANALYSIS 140
4.9.1 OVERVIEW 140
4.9.2 LOGISTIC COST SCENARIO 140
4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 140
4.9.4 CONCLUSION 141
4.10 INDUSTRY ECOSYSTEM ANALYSIS 142
4.10.1 INTRODUCTION 142
4.10.2 ECOSYSTEM ARCHITECTURE - KEY ACTORS AND ROLES 142
4.10.2.1 CORE TECHNOLOGY PROVIDERS 142
4.10.2.2 ENABLING INSTITUTIONS 142
4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS 142
4.10.3.1 RESEARCH AND DISCOVERY 142
4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION 142
4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE 143
4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION 143
4.10.4 MARKET ENABLERS AND INFRASTRUCTURE 143
4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS 143
4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE 143
4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY 143
4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS 143
4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER 143
4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING 143
4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS 143
4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES 144
4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS 144
4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK 144
4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY 144
4.10.6.4 CLINICAL OPERATIONAL BARRIERS 144
4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS 144
4.10.8 OUTLOOK - EVOLUTION OF THE ECOSYSTEM 144
4.10.9 CONCLUSION 145
4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS 146
4.11.1 INTRODUCTION 146
4.11.2 RECENT TECHNOLOGICAL INNOVATIONS 146
4.11.2.1 ADVANCED PHOTOSENSITIZERS 146
4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS 146
4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES 146
4.11.2.4 SMART NANOPLATFORMS 146
4.11.2.5 NOVEL CHEMICAL STRUCTURES 146
4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS 146
4.11.3.1 LIGHT DELIVERY DEVICES 146
4.11.3.2 COMBINATION THERAPIES 146
4.11.3.3 IMAGING INTEGRATION 146
4.11.4 KEY CHALLENGES 147
4.11.5 STRATEGIC THEMES 147
4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS 147
4.11.7 RECOMMENDATIONS 147
4.11.8 OUTLOOK AND STRATEGIC RISKS 147
4.11.9 CONCLUSION 147
4.12 PRICING ANALYSIS 148
4.12.1 INTRODUCTION 148
4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE 148
4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS 148
4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST 148
4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD 148
4.12.2.4 INDIRECT AND DOWNSTREAM COSTS 148
4.12.3 PRICING MODELS AND APPROACHES 148
4.12.3.1 COST-PLUS AND MARKUP MODELS 148
4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING 148
4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS 149
4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES 149
4.12.4 REIMBURSEMENT LANDSCAPE 149
4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS 149
4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS 149
4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS 149
4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS 149
4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS 149
4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES 149
4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY 149
4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY 150
4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT 150
4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS 150
4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS 150
4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING 150
4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES 150
4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES 150
4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS 150
4.12.8.1 FOR MANUFACTURERS 150
4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS 150
4.12.8.3 FOR PAYERS AND POLICYMAKERS 150
4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES 151
4.12.10 CONCLUSION 151
5 TARIFFS & IMPACT ON THE MARKET 152
5.1 INTRODUCTION 152
5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS 152
5.2.1 CATEGORIES OF TRADE EXPOSURE 152
5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE 152
5.3 DIRECT COST IMPACTS 152
5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION 152
5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING 152
5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS 153
5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES 153
5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS 153
5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS 153
5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS 153
5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS 153
5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS 153
5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS 153
5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS 153
5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE 153
5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS 154
5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES 154
5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY 154
5.8 RECOMMENDATIONS FOR STAKEHOLDERS 154
5.9 CONCLUSION 154
6 REGULATION COVERAGE 155
6.1 PRODUCT CODES 155
6.1.1 CERTIFIED STANDARDS 155
6.1.2 SAFETY STANDARDS 156
6.1.3 MATERIAL HANDLING & STORAGE 156
6.1.4 TRANSPORT & PRECAUTIONS 156
6.1.5 HAZARD IDENTIFICATION 156
6.1.6 CONCLUSION 157
7 MARKET OVERVIEW 158
7.1 DRIVERS 160
7.1.1 INCREASING PREVALENCE OF CANCER 160
7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES 161
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES 162
7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE 163
7.2 RESTRAINTS 164
7.2.1 LIMITED DEPTH OF LIGHT PENETRATION 164
7.2.2 HIGH COST OF TREATMENT 165
7.3 OPPORTUNITIES 166
7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES 166
7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS 167
7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA 168
7.4 CHALLENGES 169
7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY 169
7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS 170
8 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE 171
8.1 OVERVIEW 172
8.2 PHOTOSENSITIZER DRUGS 175
8.3 PHOTODYNAMIC THERAPY DEVICES 177
9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION 179
9.1 OVERVIEW 180
9.2 SKIN & CUTANEOUS ONCOLOGY 183
9.3 HEAD & NECK 184
9.4 ESOPHAGAL 186
9.5 LUNG 187
9.6 BLADDER 188
9.7 CERVICAL 190
9.8 PROSTATE 191
10 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY 192
10.1 OVERVIEW 193
10.2 STANDALONE THERAPY 196
10.3 ADJUNCTIVE THERAPY 197
10.4 PALLIATION THERAPY 197
10.5 OTHERS 198
11 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE 199
11.1 OVERVIEW 200
11.2 EXTERNAL BEAM 203
11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY 203
11.4 INTERSTITIAL (INTERNAL) DELIVERY 204
11.5 OTHERS 204
12 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE 205
12.1 OVERVIEW 206
12.2 EARLY-STAGE CANCER 209
12.3 LATE-STAGE CANCER 209
13 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS 210
13.1 OVERVIEW 211
13.2 GERIATRIC 214
13.3 ADULTS 214
13.4 PEDIATRIC 215
14 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER 216
14.1 OVERVIEW 217
14.2 HOSPITALS 220
14.3 DERMATOLOGY & SKIN-CANCER CLINICS 221
14.4 AMBULATORY SURGICAL CENTERS (ASCS) 222
14.5 ACADEMIC & RESEARCH INSTITUTES 222
14.6 OTHERS 223
15 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL 224
15.1 OVERVIEW 225
15.2 DIRECT TENDER 228
15.3 THIRD PARTY DISTRIBUTORS 228
15.4 ONLINE 229
15.5 OTHERS 229
16 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION 230
16.1 NORTH AMERICA 233
16.1.1 U.S. 244
16.1.2 CANADA 254
16.1.3 MEXICO 263
17 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY LANDSCAPE 272
17.1 COMPANY SHARE ANALYSIS: GLOBAL 272
18 SWOT ANALYSIS 273
19 COMPANY PROFILE 274
19.1 NOVERTIS AG 274
19.1.1 COMPANY SNAPSHOT 274
19.1.2 REVENUE ANALYSIS 274
19.1.3 COMPANY SHARE ANALYSIS 275
19.1.4 PRODUCT PORTFOLIO 275
19.1.5 RECENT DEVELOPMENT 275
19.2 GALDERMA S. A. 276
19.2.1 COMPANY SNAPSHOT 276
19.2.2 REVENUE ANALYSIS 277
19.2.3 COMPANY SHARE ANALYSIS 277
19.2.4 PRODUCT PORTFOLIO 278
19.2.5 RECENT DEVELOPMENTS 278
19.3 PHOTOCURE 279
19.3.1 COMPANY SNAPSHOT 279
19.3.2 REVENUE ANALYSIS 279
19.3.3 COMPANY SHARE ANALYSIS 280
19.3.4 PRODUCT PORTFOLIO 280
19.3.5 RECENT DEVELOPMENT 281
19.4 ADVANZ PHARMA CORP. 282
19.4.1 COMPANY SNAPSHOT 282
19.4.2 COMPANY SHARE ANALYSIS 282
19.4.3 PRODUCT PORTFOLIO 283
19.4.4 RECENT DEVELOPMENT 283
19.5 AMERISOURCE BERGEN CORPORATION 284
19.5.1 COMPANY SNAPSHOT 284
19.5.2 REVENUE ANALYSIS 284
19.5.3 COMPANY SHARE ANALYSIS 285
19.5.4 PRODUCT PORTFOLIO 285
19.5.5 RECENT DEVELOPMENT 286
19.6 BIOFRONTERA AG 287
19.6.1 COMPANY SNAPSHOT 287
19.6.2 REVENUE ANALYSIS 287
19.6.3 PRODUCT PORTFOLIO 288
19.6.4 RECENT DEVELOPMENTS 288
19.7 BIOLITEC HOLDING GMBH & CO KG 289
19.7.1 COMPANY SNAPSHOT 289
19.7.2 PRODUCT PORTFOLIO 289
19.7.3 RECENT DEVELOPMENT 289
19.8 CARDINAL HEALTH 290
19.8.1 COMPANY SNAPSHOT 290
19.8.2 REVENUE ANALYSIS 290
19.8.3 PRODUCT PORTFOLIO 291
19.8.4 RECENT DEVELOPMENT 292
19.9 HEMERION THERAPEUTICS 293
19.9.1 COMPANY SNAPSHOT 293
19.9.2 PRODUCT PORTFOLIO 293
19.9.3 RECENT DEVELOPMENTS 293
19.10 IMPACT BIOTECH 294
19.10.1 COMPANY SNAPSHOT 294
19.10.2 PRODUCT PORTFOLIO 294
19.10.3 RECENT DEVELOPMENTS 294
19.11 INOVA 295
19.11.1 COMPANY SNAPSHOT 295
19.11.2 PRODUCT PORTFOLIO 295
19.11.3 RECENT DEVELOPMENT 295
19.12 LUMIBIRD 296
19.12.1 COMPANY SNAPSHOT 296
19.12.2 REVENUE ANALYSIS 296
19.12.3 PRODUCT PORTFOLIO 297
19.12.4 RECENT DEVELOPMENT 297
19.13 LUZITIN 298
19.13.1 COMPANY SNAPSHOT 298
19.13.2 PRODUCT PORTFOLIO 298
19.13.3 RECENT DEVELOPMENT 298
19.14 MCKESSON 299
19.14.1 COMPANY SNAPSHOT 299
19.14.2 REVENUE ANALYSIS 299
19.14.3 PRODUCT PORTFOLIO 300
19.14.4 RECENT DEVELOPMENTS 300
19.15 MODULIGHT CORPORATION 301
19.15.1 COMPANY SNAPSHOT 301
19.15.2 REVENUE ANALYSIS 301
19.15.3 PRODUCT PORTFOLIO 302
19.15.4 RECENT DEVELOPMENT 302
19.16 ONCOLUX INC (FORMERLY LUMEDA INC.) 303
19.16.1 COMPANY SNAPSHOT 303
19.16.2 PRODUCT PORTFOLIO 303
19.16.3 RECENT DEVELOPMENT 303
19.17 SUN PHARMACEUTICAL INDUSTRIES LTD 304
19.17.1 COMPANY SNAPSHOT 304
19.17.2 REVENUE ANALYSIS 305
19.17.3 PRODUCT PORTFOLIO 305
19.17.4 RECENT DEVELOPMENT 306
19.18 THERALASE TECHNOLOGIES INC. 307
19.18.1 COMPANY SNAPSHOT 307
19.18.2 REVENUE ANALYSIS 307
19.18.3 PRODUCT PORTFOLIO 308
19.18.4 RECENT DEVELOPMENT 308
20 QUESTIONNAIRE 309
21 RELATED REPORTS 312
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security